retatrutide fatigue Side Effects Fatigue part 2 pls help

A drug that achieves more than 22% weight loss, demonstrated across two pivotal trials in distinct populations, with a well-characterised safety profile, would until recently have been considered an exceptional result

Long-term adherence is essential to realizing the full therapeutic potential of GLP-1s, yet behavioral factors (such as reaching personal weight goals or perceived social stigma) and systemic issues (like high out-of-pocket costs and fragmented care) disproportionately affect obesity patients

The drops may work for some people

The TECOS trial showed no difference between the placebo and a sitagliptin group (Table 2) [47,48,49]